Clinical Trial Update: Comparison of a Tacrolimus Hexal® Based Regimen Versus a Prograf® Based Regimen in de Novo Renal Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing tacrolimus hexal-based regimen vs Prograf-based regimen in de novo renal transplant recipients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Kidney Transplantation

Drugs mentioned

• Prograf (Tacrolimus)
• Tacrolimus Hexal (tacrolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Pharmacokinetics Study in de Novo Kidney Transplantation | Phase 4 | Status: COMPLETED | Results posted: 2019-06-17